Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Circulating IGF system and treatment outcome in epithelial ovarian cancer.

Huang YF, Cheng WF, Wu YP, Cheng YM, Hsu KF, Chou CY.

Endocr Relat Cancer. 2014 Jan 30;21(2):217-29. doi: 10.1530/ERC-13-0274. Print 2014 Apr.

2.

Analysis of IGF and IGFBP as prognostic serum biomarkers for adrenocortical carcinoma.

Patel D, Ellis R, Howard B, Boufraqech M, Gara SK, Zhang L, Quezado MM, Nilubol N, Kebebew E.

Ann Surg Oncol. 2014 Oct;21(11):3541-7. doi: 10.1245/s10434-014-3768-5. Epub 2014 May 16.

PMID:
24833102
3.

Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer.

Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D.

Tumour Biol. 2014 Apr;35(4):3125-32. doi: 10.1007/s13277-013-1405-8. Epub 2013 Nov 20.

PMID:
24254307
4.

Elevated free IGF2 levels in localized, early-stage breast cancer in women.

Espelund U, Cold S, Frystyk J, Ørskov H, Flyvbjerg A.

Eur J Endocrinol. 2008 Nov;159(5):595-601. doi: 10.1530/EJE-08-0154. Epub 2008 Aug 21.

5.

Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.

Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H.

Cancer Invest. 2008 Mar;26(2):185-92. doi: 10.1080/07357900701638343.

PMID:
18259951
6.

High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.

Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A.

Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1529-35.

PMID:
16884361
7.

IGF-I, IGF-II, IGFBP2, IGFBP3 and acid-labile subunit (ALS) in colorectal cancer patients before surgery and during one year follow up in relation to age.

Sztefko K, Hodorowicz-Zaniewska D, Popiela T, Richter P.

Adv Med Sci. 2009;54(1):51-8. doi: 10.2478/v10039-009-0017-4.

PMID:
19482725
8.

Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma.

Gao Y, Katki H, Graubard B, Pollak M, Martin M, Tao Y, Schoen RE, Church T, Hayes RB, Greene MH, Berndt SI.

Int J Cancer. 2012 Jul 15;131(2):E105-13. doi: 10.1002/ijc.26438. Epub 2011 Nov 2.

9.

Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk.

Terry KL, Tworoger SS, Gates MA, Cramer DW, Hankinson SE.

Carcinogenesis. 2009 Dec;30(12):2042-6. doi: 10.1093/carcin/bgp257. Epub .

11.

Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients.

Matuschek C, Rudoy M, Peiper M, Gerber PA, Hoff NP, Buhren BA, Flehmig B, Budach W, Knoefel WT, Bojar H, Prisack HB, Steinbach G, Shukla V, Schwarz A, Kammers K, Erhardt A, Scherer A, Bölke E, Schauer M.

Eur J Med Res. 2011 Oct 10;16(10):451-6.

12.

Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.

Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Mio T, Mishima M.

Oncol Rep. 2011 Oct;26(4):795-803. doi: 10.3892/or.2011.1354. Epub 2011 Jun 17.

PMID:
21805046
13.
14.

A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer.

Yildiz I, Tas F, Kilic L, Sen F, Saip P, Eralp Y, Keskin S, Karabulut S, Ciftci R, Serilmez M, Yasasever V, Aydiner A.

Cancer Chemother Pharmacol. 2013 Aug;72(2):437-44. doi: 10.1007/s00280-013-2212-z. Epub 2013 Jun 26.

PMID:
23801282
15.

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37.

16.

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

Abou-Alfa GK, Capanu M, O'Reilly EM, Ma J, Chou JF, Gansukh B, Shia J, Kalin M, Katz S, Abad L, Reidy-Lagunes DL, Kelsen DP, Chen HX, Saltz LB.

J Hepatol. 2014 Feb;60(2):319-24. doi: 10.1016/j.jhep.2013.09.008. Epub 2013 Sep 14.

17.

Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival.

Cao Y, Lindström S, Schumacher F, Stevens VL, Albanes D, Berndt S, Boeing H, Bueno-de-Mesquita HB, Canzian F, Chamosa S, Chanock SJ, Diver WR, Gapstur SM, Gaziano JM, Giovannucci EL, Haiman CA, Henderson B, Johansson M, Le Marchand L, Palli D, Rosner B, Siddiq A, Stampfer M, Stram DO, Tamimi R, Travis RC, Trichopoulos D, Willett WC, Yeager M, Kraft P, Hsing AW, Pollak M, Lin X, Ma J.

J Natl Cancer Inst. 2014 Jun;106(6):dju085. Erratum in: J Natl Cancer Inst. 2014 Jun;106(6):dju194.

18.

The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.

So KA, Hong JH, Jin HM, Kim JW, Song JY, Lee JK, Lee NW.

Gynecol Oncol. 2014 Mar;132(3):551-5. doi: 10.1016/j.ygyno.2014.01.010. Epub 2014 Jan 14.

PMID:
24440470
19.

Pretreatment CA 15-3 levels do not predict disease-free survival in patients with advanced epithelial ovarian cancer.

Gemer O, Oustinov N, Gdalevich M, Dubnik S, Levy R, Yachnin A, Lavie O, Ben Baruch N, Ben Arie A.

Tumori. 2013 Mar-Apr;99(2):257-60. doi: 10.1700/1283.14201.

PMID:
23748823
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk